Skip to content

UG3 Pilot Clinical Trial

Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - UG3 Pilot Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07073898
Enrollment
65
Registered
2025-07-18
Start date
2025-09-26
Completion date
2026-01-27
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

LungSMART Utah utilizes a Population Health Management (PHM) approach that addresses key barriers to Lung Cancer Screening (LCS) implementation by deploying a centralized Hub infrastructure for eligibility assessment, individualized risk assessment and Shared Decision Making (SDM), LCS referral, and screening completion assistance, thereby increasing LCS reach at scale among Community Health Centers (CHCs) patients across the state of Utah.

Detailed description

LungSMART Utah is a Sequential Multiple Assignment Randomized Trial (SMART) that promotes the reach of lung cancer screening (LCS) among patients who receive medical services at Utah Community Health Centers (CHCs). The study design consists of two sequential stages: an Eligibility Assessment phase to identify and engage individuals at risk to participate in a shared decision-making (SDM) session to assess LCS eligibility, recommendation, and preference, followed by an LCS Completion phase to promote follow-through with recommended screening. In this pilot trial, 50 current or former tobacco users aged 50-80 who receive medical services at the Mountainlands CHC and have no recorded history of lung cancer and have not participated in a SDM about LCS will be identified for the study. In the Eligibility Assessment Phase, patients will be assessed for LCS eligibility through digital health interventions and, if eligible, will engage with a qualified registered nurse (RN) at a centralized "Hub" for a SDM session, with and be offered a referral for LCS if screening is recommended and preferred. Phase 1 interventions include repeated text messaging (TM+), conversational agent (CA), and educational video (VID) to engage patients in a SDM session. The LCS Completion phase evaluates telehealth interventions designed to address logistical barriers and hesitancy among referred patients in completing LCS. Interventions include CA and either proactive- or reactive-patient navigation (PN) to increase LCS completion among CHC patients. Clinic staff will also be queried to examine if further refinement of research workflow and procedures is needed. Mountainlands CHC has agreed to partner with us to recruit patient participants for this pilot study.

Interventions

OTHERRepeated Text Messages (TM+)

The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages).

The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM.

OTHEREducational Video

The educational video provides patients with information and answers commonly asked questions about LCS.

Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own.

Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS.

Sponsors

University of Utah
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Is currently a patient at Mountainlands CHCs * Speak English or Spanish * Current or former male or female smokers * Age 50-80 * Have a phone that can receive text messages * Electronic health records indicate they have not opted out of receiving text contact from the clinic

Exclusion criteria

* Persons with lung cancer or previous SDM

Design outcomes

Primary

MeasureTime frameDescription
Engagement - Lung Cancer Screening (LCS)up to 3 months from study enrollmentThis outcome measure will report the proportion of enrolled subjects who engaged with Lung Cancer Screening (LCS) text messages during the study period. LCS Engagement will be defined as any documented interaction with the text messaging system, as recorded by the study platform.
Engagement - Shared Decision Making (SDM)up to 3 months from study enrollmentThis outcome measure will report the proportion of enrolled subjects who engaged with Shared Decision Making (SDM) conversations during the study period. SDM Engagement will be defined as any documented interaction with SDM conversations, as recorded in study documentation.

Secondary

MeasureTime frameDescription
Trustworthinessup to 3 months from study enrollmentSurvey questions will measure engagement, trustworthiness, acceptability, and usefulness related to all interventions and content. Text message trustworthiness is measured by two items that directly ask what made participants trust or not trust the initial text message. This outcome measure will report the proportion of subjects who reported text message trustworthiness.
Acceptabilityup to 3 months from study enrollmentSurvey questions will measure engagement, trustworthiness, acceptability, and usefulness related to all interventions and content. Acceptability is measured as a composite of 4 dimensions: * Frequency: 3 items about text message frequency and call attempt frequency * Pace: 2 items about information delivery pace * Process: 1 item about technical issues, 2 items regarding improvement suggestions, and 3 open-ended questions about the overall experience * Content: 4 Yes/No items about the educational video in the branching logic section. This outcome measure will report the proportion of subjects who reported text message acceptability.
Usefulnessup to 3 months from study enrollmentSurvey questions will measure engagement, trustworthiness, acceptability, and usefulness related to all interventions and content. Usefulness is measured as a composite of 4 dimensions: * Perceived helpfulness: 1 question about the helpfulness of reminder texts, and 1 branching logic question about the helpfulness of additional information provided by the educational video that arrives via text. * Confidence outcomes: 1 question measuring confidence in the next steps after shared decision-making * Functional utility: 2 questions about opportunities to ask questions/express concerns and suggestions for additional valuable resources * Overall utility: 2 closing questions about what worked well and the experience with the program. This outcome measure will report the proportion of subjects who reported text message usefulness.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDavid Wetter, Ph.D.

Huntsman Cancer Institute/ University of Utah

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026